IDEKOS is dedicated to the development of products for diseases linked to an overexpression of TG2. The primary focus is Celiac Disease.
IDEKOS develops compounds that target TG2, the critical enzyme in the pathogenesis of the celiac disease. Several potent, small molecule inhibitors of TG2 from different chemical series have been identified. These molecules with composition of matter patents are a mix of reversible and irreversible inhibitors, show sub-micromolar to low nanomolar activity in BC assays and are selective to TG2. One has shown activity against the target in vivo.